Published in Cancer Res on November 01, 2005
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
Tumor clone dynamics in lethal prostate cancer. Sci Transl Med (2014) 2.93
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res (2012) 2.81
The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell (2012) 2.69
Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol (2008) 2.35
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res (2009) 1.71
An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest (2013) 1.64
Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol (2013) 1.28
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res (2014) 1.27
Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol (2012) 1.25
Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm Res (2006) 0.97
Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem (2007) 0.96
Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer. Proc Natl Acad Sci U S A (2011) 0.92
Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer. Int J Mol Sci (2013) 0.89
Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer. Clin Cancer Res (2016) 0.87
Insights into Chemoresistance of Prostate Cancer. Int J Biol Sci (2015) 0.86
Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening. Mol Pharm (2014) 0.83
Role of signaling transduction pathways in development of castration-resistant prostate cancer. Prostate Cancer (2011) 0.83
Hic-5 controls BMP4 responses in prostate cancer cells through interacting with Smads 1, 5 and 8. Oncogene (2011) 0.83
Human prostate cancer heterotransplants: a review on this experimental model. Asian J Androl (2010) 0.83
Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy. Oncotarget (2015) 0.82
Retracted erbB expression changes in ethanol and 7,12- dimethylbenz (a)anthracene-induced oral carcinogenesis. Med Oral Patol Oral Cir Bucal (2013) 0.81
Serially heterotransplanted human prostate tumours as an experimental model. J Cell Mol Med (2009) 0.80
Structure-based virtual screening and identification of a novel androgen receptor antagonist. J Biol Chem (2012) 0.80
Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer. World J Urol (2011) 0.78
Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med (2016) 0.77
Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants. Invest New Drugs (2009) 0.77
20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer. PLoS One (2014) 0.77
Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies. Indian J Surg Oncol (2016) 0.76
Establishment of patient-derived cancer xenografts in immunodeficient NOG mice. Int J Oncol (2015) 0.76
Methylselenocysteine preventing castration-resistant progression of prostate cancer. Prostate (2015) 0.75
Arabilin overcomes resistance to AR-targeted therapy. J Antibiot (Tokyo) (2017) 0.75
Role of steroid receptor and coregulator mutations in hormone-dependent cancers. J Clin Invest (2017) 0.75
Sequential maximum androgen blockade (MAB) in minimally symptomatic prostate cancer progressing after initial MAB: two case reports. Cancer Biol Med (2014) 0.75
Patient-derived xenografts as in vivo models for research in urological malignancies. Nat Rev Urol (2017) 0.75
BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients. Oncotarget (2016) 0.75
Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol (2017) 0.75
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. J Clin Invest (2017) 0.75
Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-κB. Invest New Drugs (2013) 0.75
Clinical relevance of androgen receptor alterations in prostate cancer. Endocr Connect (2017) 0.75
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell (2002) 6.32
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell (2005) 3.51
Mitochondrial genome variation in eastern Asia and the peopling of Japan. Genome Res (2004) 3.34
Laparoscopic radical nephroureterectomy: a multicenter analysis in Japan. Eur Urol (2009) 2.97
Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet (2010) 2.92
Physical finding of nutcracker phenomenon. Kidney Int (2013) 2.60
Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med (2009) 2.30
Cortical organization by the septin cytoskeleton is essential for structural and mechanical integrity of mammalian spermatozoa. Dev Cell (2005) 2.21
Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol (2007) 2.05
Efficacy of nondrug lifestyle measures for the treatment of nocturia. J Urol (2010) 1.94
Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol (2002) 1.85
Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol (2006) 1.80
XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet (2004) 1.76
Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem (2003) 1.75
Involvement of urinary bladder Connexin43 and the circadian clock in coordination of diurnal micturition rhythm. Nat Commun (2012) 1.74
Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol (2006) 1.68
Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients. Int J Urol (2010) 1.65
Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet (2012) 1.59
Laparoscopic partial nephrectomy using microwave tissue coagulator for small renal tumors: usefulness and complications. Eur Urol (2004) 1.55
Regulation of connexin 43 by basic fibroblast growth factor in the bladder: transcriptional and behavioral implications. J Urol (2011) 1.48
Involvement of vertebrate polkappa in Rad18-independent postreplication repair of UV damage. J Biol Chem (2002) 1.48
Objective patterning of uroflowmetry curves in children with daytime and nighttime wetting. J Urol (2010) 1.41
A polymorphism of the POLG2 gene is genetically associated with the invasiveness of urinary bladder cancer in Japanese males. J Hum Genet (2011) 1.39
Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol (2007) 1.34
Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction. Am J Physiol Heart Circ Physiol (2006) 1.32
Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis (2006) 1.31
Adult case of an omphalomesenteric cyst resected by laparoscopic-assisted surgery. World J Gastroenterol (2006) 1.28
Discrepancy between local and central pathological review of radical prostatectomy specimens. J Urol (2010) 1.24
Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol (2004) 1.22
Solid pancreatic hamartoma. Pathol Int (2007) 1.22
Tumor necrosis factor-alpha is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction. Am J Physiol Heart Circ Physiol (2007) 1.20
Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. J Cancer Res Clin Oncol (2008) 1.19
Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. J Endourol (2010) 1.18
Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin Cancer Res (2008) 1.18
Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol (2006) 1.16
Collagenous matrices as release carriers of exogenous growth factors. Biomaterials (2004) 1.14
A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol (2006) 1.13
Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. J Urol (2004) 1.13
Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990-2000 in Japan. Eur Urol (2004) 1.13
Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int (2014) 1.12
Percutaneous drainage and continuous irrigation in patients with severe pyogenic spondylitis, abscess formation, and marked bone destruction. J Neurosurg Spine (2006) 1.12
High 18F-fluorodeoxyglocose uptake in adrenal histoplasmosis; a case report. Eur Radiol (2005) 1.12
Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity. J Cell Biochem (2009) 1.12
Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol (2002) 1.11
Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin Cancer Res (2008) 1.11
Characterization of loss-of-inactive X in Klinefelter syndrome and female-derived cancer cells. Oncogene (2004) 1.11
Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol (2011) 1.11
Septins as diagnostic markers for a subset of human asthenozoospermia. J Urol (2008) 1.09
The roles of supernumerical X chromosomes and XIST expression in testicular germ cell tumors. J Urol (2003) 1.08
Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology (2005) 1.08
Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res (2010) 1.08
Induction of smooth muscle cell-like phenotype in marrow-derived cells among regenerating urinary bladder smooth muscle cells. Am J Pathol (2005) 1.07
Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol (2008) 1.06
STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol (2007) 1.06
Association of genetic polymorphisms at 8q24 with the risk of prostate cancer in a Japanese population. Prostate (2008) 1.05
Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population. Cancer Lett (2003) 1.04
Case of chronic pancreatitis involving an autoimmune mechanism that extended to retroperitoneal fibrosis. Pancreas (2003) 1.02
Feasibility and safety of laparoscopic and endoscopic cooperative surgery for gastric submucosal tumors, including esophagogastric junction tumors. Dig Endosc (2013) 1.02
The importance of integrin-linked kinase in the regulation of bladder cancer invasion. Int J Cancer (2011) 1.02
Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res (2003) 1.01
[A case report of renal cell carcinoma with metastatic intraductal tumor thrombus of the common bile duct]. Hinyokika Kiyo (2009) 1.01
Bladder regeneration by bladder acellular matrix combined with sustained release of exogenous growth factor. J Urol (2003) 1.00
Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep (2008) 0.99
Retroperitoneoscopic ureterocutaneostomy for obstructive uropathy with advanced bladder cancer: a case report. Int J Urol (2002) 0.99
Escherichia coli isolates associated with uncomplicated and complicated cystitis and asymptomatic bacteriuria possess similar phylogenies, virulence genes, and O-serogroup profiles. J Clin Microbiol (2006) 0.99
A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression. Hum Mol Genet (2010) 0.99
Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species. Cancer Res (2007) 0.99
Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. Drug Metab Pharmacokinet (2012) 0.98
Type I collagen can function as a reservoir of basic fibroblast growth factor. J Control Release (2004) 0.98
Pannexin 1 involvement in bladder dysfunction in a multiple sclerosis model. Sci Rep (2013) 0.98
Distribution of the usp gene in uropathogenic Escherichia coli isolated from companion animals and correlation with serotypes and size-variations of the pathogenicity island. Microbiol Immunol (2003) 0.97
Requirement of androgen-dependent activation of protein kinase Czeta for androgen-dependent cell proliferation in LNCaP Cells and its roles in transition to androgen-independent cells. Mol Endocrinol (2006) 0.97